BRAF and Miyoshi myopathy: Although Vemurafenib has shown significant effects in the pre-treatment of patients with BRAF V600E mutation, patients are prone to develop resistance to it, such that 80% of MM patients treated for 3 years have shown resistance to Vemurafenib [67].